Literature DB >> 11863116

Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.

J Baselga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11863116     DOI： 10.1093/annonc/mdf092

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  Schistosomiasis--a century searching for chemotherapeutic drugs.

Authors:  Gabriela Ribeiro-dos-Santos; Sergio Verjovski-Almeida; Luciana C C Leite
Journal:  Parasitol Res       Date:  2006-04-25       Impact factor: 2.289

2.  Inhibition of breast cancer progression by a novel histone deacetylase inhibitor, LW479, by down-regulating EGFR expression.

Authors:  Jingjie Li; Tao Zhang; Feifei Yang; Yuan He; Fujun Dai; Dan Gao; Yihua Chen; Mingyao Liu; Zhengfang Yi
Journal:  Br J Pharmacol       Date:  2015-06-12       Impact factor: 8.739

3.  TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway.

Authors:  Wei Jin; Bo-bin Chen; Ji-yu Li; Hua Zhu; Mark Huang; Sheng-mei Gu; Qiao-qiao Wang; Jia-ying Chen; Sanjian Yu; Jiong Wu; Zhi-ming Shao
Journal:  Mol Cell Biol       Date:  2011-10-24       Impact factor: 4.272

4.  Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression.

Authors:  Xiang-Hong Peng; Prasanthi Karna; Zehong Cao; Bing-Hua Jiang; Muxiang Zhou; Lily Yang
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

Review 5.  Targeting protein quality control pathways in breast cancer.

Authors:  Sara Sannino; Jeffrey L Brodsky
Journal:  BMC Biol       Date:  2017-11-16       Impact factor: 7.431

6.  HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

Authors:  Anthony Kong; Véronique Calleja; Pierre Leboucher; Adrian Harris; Peter J Parker; Banafshé Larijani
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

7.  The efficacy of Herceptin therapies is influenced by the expression of other erbB receptors, their ligands and the activation of downstream signalling proteins.

Authors:  B L Smith; D Chin; W Maltzman; K Crosby; G N Hortobagyi; S S Bacus
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.